Hyperparathyroidism Epidemiology Forecast 2026-2035

Read more about this report - Request a Free Sample

Hyperparathyroidism Epidemiology Forecast Report Coverage

Expert Market Research's “Hyperparathyroidism Epidemiology Forecast Report 2026-2035” offers comprehensive information on the prevalence and demographics of hyperparathyroidism. It projects the future incidence and prevalence rates of hyperparathyroidism cases across various populations. The study covers age, gender, and type as major determinants of the hyperparathyroidism population. The report highlights patterns in the prevalence of hyperparathyroidism over time and projects future trends based on multiple variables.

Hyperparathyroidism Understanding: Disease Overview

Hyperparathyroidism is a disorder characterized by excessive secretion of parathyroid hormone (PTH), leading to hypercalcemia and disturbances in bone, kidney, and mineral metabolism. It is classified as primary (parathyroid adenomas or hyperplasia), secondary (response to chronic hypocalcemia, often in chronic kidney disease), or tertiary (autonomous PTH secretion following long-standing secondary disease). Symptoms may include bone pain, kidney stones, fatigue, and neuropsychiatric manifestations. Early detection is important to prevent complications such as osteoporosis, cardiovascular disease, and renal impairment.

Hyperparathyroidism Epidemiology Perspective

The hyperparathyroidism epidemiology division offers information on the patient pool from history to the present, as well as the projected trend for each of the 8 major markets. Expert Market Research provides both current and predicted trends for the hyperparathyroidism epidemiology scenario by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for hyperparathyroidism and their trends. The hyperparathyroidism detailed epidemiology segmentation is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.

• The global incidence of primary hyperparathyroidism (PHPT) shows considerable variation, ranging between 13 and 120 cases per 100,000 individuals annually, influenced by regional screening practices and healthcare accessibility.
• Primary hyperparathyroidism (PHPT) is the most widely recognized form and is caused by autonomous overproduction of parathyroid hormone by one or more parathyroid glands. PHPT disproportionately affects women, particularly post-menopausal women. In population-based data from Scotland, about 72.3% of new cases were female.
• The incidence of primary hyperparathyroidism (PHPT) escalates notably with age, increasing from 12-24 per 100,000 in individuals under 50 to 95-196 per 100,000 among those aged 70-79 years.
• Because secondary hyperparathyroidism (SHPT) is often driven by CKD and associated mineral/bone disorders, its epidemiology is tightly linked to CKD prevalence and healthcare access. A 2024 meta-analysis across 21 studies with 110,977 CKD patients estimated the global pooled prevalence of CKD-related SHPT at 49.5% (95% CI: 30.20–68.18), irrespective of diagnostic criteria used.

Read more about this report - Request a Free Sample

Country-wise Hyperparathyroidism Epidemiology Segment

The hyperparathyroidism epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

In the United States, the epidemiology of hyperparathyroidism reflects a steady increase in detection rates, largely attributed to improved biochemical screening and greater clinical awareness. Recent estimates indicate an incidence of approximately 48.3-50.4 cases per 100,000 person-years among women, highlighting both the gender disparity and the influence of age-related endocrine changes. The predominance of cases in postmenopausal women underscores hormonal and metabolic risk factors. Continued national surveillance and public health initiatives are crucial to ensure timely diagnosis and optimal management of hyperparathyroidism across diverse populations.

Hyperparathyroidism: Treatment Overview

Treatment depends on type and severity. Primary hyperparathyroidism often requires surgical parathyroidectomy, which is curative in most cases. Secondary and tertiary forms focus on correcting underlying causes, such as vitamin D supplementation, phosphate binders, or managing chronic kidney disease. Calcimimetics (e.g., cinacalcet) help control PTH levels when surgery is not feasible. Regular monitoring of calcium, phosphate, and bone density is critical. Multidisciplinary management ensures prevention of bone, renal, and cardiovascular complications, improving long-term outcomes and quality of life in patients with hyperparathyroidism.

Key Questions Answered

• What are the key findings of hyperparathyroidism epidemiology in the 8 major markets?
• What will be the total number of patients with hyperparathyroidism across the 8 major markets during the forecast period?
• What was the country-wise hyperparathyroidism epidemiology scenario in the 8 major markets in the historical period?
• Which country will have the highest number of cases of hyperparathyroidism during the forecast period of 2026-2035?
• Which key factors would influence the shift in the patient population of hyperparathyroidism during the forecast period of 2026-2035?
• What are the currently available treatments for hyperparathyroidism?
• What are the disease risks, signs, symptoms, and unmet needs of hyperparathyroidism?

Scope of the Hyperparathyroidism Epidemiology Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of hyperparathyroidism based on several factors.
• Hyperparathyroidism Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The hyperparathyroidism report helps to identify the patient population, and the unmet needs are highlighted along with an assessment of the disease's risk and burden.

Related Reports

Thyroid Gland Disorder Treatment Market

Anaplastic Thyroid Cancer Pipeline Analysis